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abstract
PURPOSE The MURANO study demonstrated signiﬁcant progression-free survival (PFS) beneﬁt for ﬁxed-
duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lym-
phocytic leukemia. With all patients off treatment, we report minimal residual disease (MRD) kinetics and
updated outcomes.
METHODS Patients were randomly assigned to 2 years of venetoclax plus rituximab during the ﬁrst six cycles, or
six cycles of bendamustine-rituximab. Primary end point was PFS. Safety and peripheral blood (PB) MRD
status—at cycle 4, 2 to 3 months after end of combination therapy (EOCT), and every 3 to 6 months there-
after—were secondary end points.
RESULTS Of 194 patients, 174 (90%) completed the venetoclax-rituximab phase and 130 (67%) completed
2 years of venetoclax. With a median follow-up of 36 months, PFS and overall survival remain superior to
bendamustine-rituximab (hazard ratio, 0.16 [95% CI, 0.12 to 0.23]; and hazard ratio, 0.50 [95% CI, 0.30 to
0.85], respectively). Patients who received venetoclax-rituximab achieved a higher rate of PB undetectableMRD
(uMRD; less than 1024) at EOCT (62% v 13%) with superiority sustained through month 24 (end of therapy).
Overall, uMRD status at EOCT predicted longer PFS. Among those with detectable MRD, low-level MRD (1024 to
less than 1022) predicted improved PFS compared with high-level MRD (1022 or greater). At a median of
9.9 months (range, 1.4 to 22.5 months) after completing ﬁxed-duration venetoclax-rituximab, overall only 12%
(16 of 130) of patients developed disease progression (11 high-level MRD, three low-level MRD). At the end
of therapy, 70% and 98% of patients with uMRD remained in uMRD and without disease progression,
respectively.
CONCLUSION With all patients having ﬁnished treatment, continued beneﬁt was observed for venetoclax-
rituximab compared with bendamustine-rituximab. uMRD rates were durable and predicted longer PFS, which
establishes the impact of PB MRD on the beneﬁt of ﬁxed-duration, venetoclax-containing treatment. Low
conversion to detectable MRD and sustained PFS after completion of 2 years of venetoclax-rituximab dem-
onstrate the feasibility of this regimen.
J Clin Oncol 37:1-9. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is amalignancy of
mature CD5+ B cells.1 Treatment options for relapsed/
refractory (R/R) disease have evolved from rituximab
monotherapy or chemoimmunotherapy (CIT), including
bendamustine-rituximab,2 to such novel agents as the
kinase inhibitors ibrutinib3 or idelalisib,4 resulting in
improved progression-free survival (PFS) and overall
survival (OS). However, these novel therapies require
continuous treatment to disease progression, which can
be problematic as a result of patient intolerance,5 the
high cost of therapy,6 and potential for selecting re-
sistant subclones.7 There is therefore a need for efﬁ-
cacious ﬁxed-duration targeted treatments.
Venetoclax is a highly selective inhibitor of B-cell
lymphoma 2, an antiapoptotic protein that is consti-
tutively overexpressed in CLL.8,9 Venetoclax acts in-
dependently of functional TP5310 and has proven
efﬁcacy in patients with heavily pretreated CLL.11,12
Deep remissions, including eradication of minimal
residual disease (MRD) in blood or marrow, are de-
sirable therapeutic goals in patients with CLL, as
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attainment of undetectable MRD (uMRD) after CIT is as-
sociated with prolonged PFS and OS.13-18 Venetoclax
combined with rituximab, followed by continuous ven-
etoclax monotherapy, can result in such deep remissions19
and is therefore the ﬁrst novel agent that might allow for
a ﬁxed-duration regimen. Whether MRD levels predict
clinical outcome with such a regimen is currently unknown.
We compared the efﬁcacy and safety of ﬁxed-duration
venetoclax-rituximab in R/R CLL with standard bendamustine-
rituximab in the phase III MURANO study. At the time of the
preplanned analysis of the primary end point, the majority
of patients in the venetoclax-rituximab arm were still re-
ceiving venetoclax monotherapy. Analysis revealed that
venetoclax-rituximab–treated patients had signiﬁcantly
superior PFS and increased rates of uMRD compared with
bendamustine-rituximab–treated patients.20 With this
follow-up and all patients now having completed therapy,
we present analyses of clinical outcomes and the impact of
MRD levels on these outcomes with ﬁxed-duration,
venetoclax-based therapy.
METHODS
Study Design and Conduct
MURANO (ClinicalTrials.gov identiﬁer: NCT02005471) is
an ongoing global, phase III, open-label, randomized study
investigating the efﬁcacy and safety of venetoclax-rituximab
therapy compared with bendamustine-rituximab in patients
with R/R CLL. Eligibility criteria and study design have been
described previously.20 The trial was conducted in accor-
dance with the Declaration of Helsinki and the International
Conference on Harmonisation of Good Clinical Practice
guidelines.21,22 The trial protocol was approved by the
ethics committee at each participating institution. All pa-
tients provided written informed consent to participate.
Treatment
Patients were randomly assigned 1:1 to receive six 28-day
cycles of venetoclax-rituximab followed by venetoclax
400 mg once per day for a total of 2 years—calculated from
day 1 of cycle 1 after the venetoclax dose ramp-up— or six
cycles of standard bendamustine-rituximab,2 unless dis-
ease progression or unacceptable toxicity occurred sooner.
Dosing, prophylactic measures, and monitoring were as
described previously.20
Assessments
Primary efﬁcacy end point was investigator-assessed PFS,
which was deﬁned as the time from random assignment to
the ﬁrst occurrence of progression, relapse, or death,
whichever occurred ﬁrst. Peripheral blood (PB) MRD status
2 to 3 months after the end of combination therapy (EOCT)
was a secondary end point and was also assessed at cycle 4
and every 3 to 6 months after EOCT. Other end points
included clinical response—OS, complete response (CR),
and partial response (PR)—and safety assessments. All
patients were observed for safety and efﬁcacy every 3 to
6 months through year 3 from initiation of combination
therapy. Disease status was assessed by computed to-
mography (CT) scan at screening, cycle 4, and the EOCT
visit. During the venetoclax single-agent treatment period
and at follow-up visits, response was assessed clinically. As
the duration of venetoclax treatment from cycle 1, day 1
was 2 years, the time of treatment cessation is closest to the
protocol-deﬁned visit that occurred at approximately month
24 and was therefore considered to be the end of treatment
(EOT) visit.
Central analysis of serial PB MRD samples was performed
using allele-speciﬁc oligonucleotide–polymerase chain
reaction (ASO-PCR) and/or ﬂow cytometry on the basis of
the European Research Initiative on CLL four-color assay
(details in the Data Supplement). A hierarchical algorithm
was used to determine MRD status using both methodol-
ogies (Appendix Table A1, online only). MRD was con-
sidered undetectable (uMRD) if the result was less than one
CLL cell in 10,000 leukocytes (MRD value less than
0.0001, 1024). Low-level (L-)MRD was deﬁned as 1024 to
less than 1022, and high-level (H-)MRD 1022 or greater.
Safety evaluation included the monitoring of adverse events
(AEs), premature study withdrawals, deaths, and ven-
etoclax dose delays.
Statistical Analyses
At a preplanned interim analysis, the independent data
monitoring committee recommended that the study un-
dergo full analysis because the prespeciﬁed statistical
boundaries for PFS were crossed—this became the pri-
mary analysis, which was published earlier.20 There is no
alpha spending allocated to the current analysis of end
points, performed with one more year of follow-up after the
primary analysis. All P values are therefore descriptive.
Kaplan-Meier estimates were used to analyze the time-to-
event data. Log-rank test and Cox proportional hazards
regression model—stratiﬁed by del(17p) status, risk status,
and geographic region—were used to compare PFS and
OS across arms. Fisher’s exact test was performed to
compare MRD status and clinical and cytogenetic risk
factors in venetoclax-rituximab patients with and without
progressive disease (PD) after EOT.
RESULTS
Patients
The MURANO study enrolled 389 patients globally—194
patients in the venetoclax-rituximab arm and 195 in the
bendamustine-rituximab arm (Appendix Fig A1, online
only)—with well-balanced demographic and baseline
disease characteristics.20 Current data were analyzed using
a cutoff date of May 8, 2018, when all patients were off
treatment. In the venetoclax-rituximab arm, 174 patients
(90%) completed the venetoclax-rituximab combination
phase and 130 (65%) completed 2 years of planned
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venetoclax without PD. The remainder of the patients re-
ceiving venetoclax-rituximab had PD (11%), died without
PD (1%), or withdrew as a result of AEs (15%; Appendix
Table A2, online only) or for another reason (6%). Char-
acteristics of those with PD on therapy are shown in Ap-
pendix Table A3 (online only). Of those who withdrew from
venetoclax treatment because of an AE (n = 32), 10 remain
free from PD; 10 had PD, ﬁve of whom received subsequent
treatment; eight died because of the AE; and four died as
a result of a different AE. Median venetoclax treatment
duration from the start of ramp-up was 24.4months (range,
0.1 to 27.9 months) and the relative dose intensity was
97.4% (range, 26% to 100%; Appendix Table A4, online
only).
Efﬁcacy
At a median follow-up of 36.0 months, PFS with venetoclax-
rituximab was superior to bendamustine-rituximab (hazard
ratio [HR], 0.16 [95% CI, 0.12 to 0.23]; P , .001; median
not reached v 17.0 months; Fig 1A). Three-year PFS es-
timates were 71.4% (95% CI, 64.8% to 78.1%) and 15.2%
(95% CI, 9.1% to 21.4%), respectively. A consistent
magnitude of treatment effect on PFS with venetoclax-
rituximab was observed in all clinical and biologic sub-
groups (Appendix Fig A2, online only).
In the 130 patients who completed 2 years of venetoclax
without PD, the 6- and 12-month PFS estimates from
venetoclax cessation were 92% (95% CI, 87.3% to 96.8%)
and 87% (95% CI, 81.1% to 93.8%), respectively (Fig 2),
with a median of 9.9 months (range, 1.4 to 22.5 months) of
follow-up off venetoclax. In univariate analysis, the pres-
ence of del(17p) and/or TP53mutation and the absence of
del(11q) were associated with risk of PD after venetoclax
cessation (both P, .03; Table 1). However, the number of
events in del(11q) patients was small (n = 1) and the effect
diminished when Do¨hner hierarchical testing was applied
to evaluate del(11) cases without del(17p) (P = .25).
In this analysis, improvement in OS was observed with
venetoclax-rituximab compared with bendamustine-
rituximab (HR, 0.50 [95% CI, 0.30 to 0.85]; P = .0093;
3-year estimate: 87.9% v 79.5%; Fig 1B). Median time to
next anti-CLL treatment or death was 23.9 months (range,
0.0 to 43.7 months) in the bendamustine-rituximab
arm—there were too few patients at risk for this to be re-
liably assessed in the venetoclax-rituximab arm. Sub-
sequent CLL-directed treatment administered after PD in
91 patients in the bendamustine-rituximab arm (Appendix
Table A5, online only). Of these, 71 patients (78.0%)
No. at risk:
VenR 194 190 185 179 176 174 170 167 161 150 135 99 61 21 6 2 1
BR 195 178 164 142 128 103 84 79 65 55 41 26 10 2
Time (months)
20
PF
S
100
80
60
40
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51
VenR (n = 194)
BR (n = 195)
Censored
VenR (n = 194)
BR (n = 195)
Censored
HR, 0.16 (95% CI, 0.12 to 0.23); P < .001
No. at risk:
VenR 194 190 185 183 182 179 178 176 173 168 163 128 87 39 13 4
9 1
2
BR 195 181 175 167 162 155 152 150 147 141 136 111 76 34
Time (months)
20
OS
100
80
60
40
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51
HR, 0.50 (95% CI, 0.30 to 0.85); P = .0093
A B
FIG 1. (A and B) Kaplan-Meier plot of (A) investigator-assessed progression-free survival (PFS) and (B) overall survival (OS) in the intention-to-treat
population with 36-month median follow up. BR, bendamustine-rituximab; HR, hazard ratio; VenR, venetoclax-rituximab.
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FIG 2. Kaplan-Meier plot of progression-free survival (PFS) for patients
who completed 2 years of venetoclax without prior disease progression
(n = 130; median follow-up of 9.9 months off venetoclax). VenR,
venetoclax-rituximab.
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received novel targeted agents, including 46 who received
ibrutinib and seven who received venetoclax as next-line
treatment. In the venetoclax-rituximab arm, 27 (13.9%) of
194 patients received subsequent therapy—13 (48.1%) of
27 patients received novel targeted agents as next treat-
ment after PD, including eight who received ibrutinib and
three who were retreated with venetoclax. Of those patients
who received ibrutinib after venetoclax, two achieved PR,
and efﬁcacy data were unavailable for the remaining six
patients. Among the three patients who were retreated with
venetoclax, one achieved PR, one had stable disease, and
one lacked follow-up efﬁcacy data.
MRD at EOCT
MRD status assessed using ASO-PCR, and ﬂow cytometry
demonstrated high correlation (r = .89) and concordance
(Data Supplement and Appendix Fig A3, online only).
There was also high concordance for MRD status between
PB and bone marrow. Of 49 uMRD in PB, 44 (90%) were
conﬁrmed in bone marrow in available paired samples
among patients who received venetoclax-rituximab (from
47 patients; Appendix Fig A4, online only). Higher rates of
PB uMRD were observed in the venetoclax-rituximab arm
than in the bendamustine-rituximab arm at EOCT (Table 2)
and all assessments during and after venetoclax single-
agent treatment (Fig 3A). H-MRD at EOCT was less
frequent with venetoclax-rituximab (4.6%) than with
bendamustine-rituximab (29.2%; Table 2). Overall, the
rate of uMRD as best MRD response at any time during the
study was higher with venetoclax-rituximab (82.5%) than
with bendamustine-rituximab (23.1%).
At EOCT, patients with uMRD had a longer duration of PFS
in each treatment arm (Fig 3B) than patients with de-
tectable MRD. Among patients with detectable MRD, those
with L-MRD had a longer duration of PFS compared with
patients with H-MRD for either treatment arm (venetoclax-
rituximab: HR, 0.24 [95% CI 0.08 to 0.72]; bendamustine-
rituximab: HR, 0.22 [95% CI 0.13 to 0.38]). However, there
were only six patients with H-MRD at EOCT in the
venetoclax-rituximab arm.
Landmark analysis from EOCT demonstrated that patients
in the venetoclax-rituximab arm who achieved an
investigator-assessed PR with uMRD had PFS outcomes
that were similar to those of patients who achieved CR with
uMRD (Fig 3C; HR, 0.71 [95% CI, 0.24 to 2.14]). Con-
versely, patients who achieved PR/nodular PR with de-
tectable MRD had inferior PFS compared with those with
PR and uMRD from 18 months onwards after EOCT. Pa-
tients who achieved CR with detectable MRD—all of whom
had L-MRD—had a PFS that was comparable to that of
patients who achieved uMRD at this follow-up, although the
number of such patients is small (HR, 1.07 [95% CI 0.12 to
9.55]; Fig 3C).
MRD Kinetics
High rates of uMRD and L-MRD in the venetoclax-rituximab
arm at EOCT were sustained with serial assessments
(Appendix Fig A5A, online only) and also found at EOT
among 130 patients who completed 2 years of venetoclax
(uMRD: 83 [64%] of 130 patients; and L-MRD: 23 [18%] of
130 patients).
At this follow-up—median of 9.9 months off venetoclax—
only two of 83 patients who were uMRD at EOT (2.4%)
developed PD. Of the patients who had detectable
TABLE 1. MRD Status and Clinical and Cytogenetic Risk Factors for PD in
Venetoclax-Rituximab Arm Patients Alive Without Disease Progression at Month 24
(n = 130; univariate analysis)
Feature (No.)* No. (%) With PD P†
PB MRD at EOT (month 24)‡ , .001
uMRD (n = 83) 2 (2.4)
L-MRD (n = 23) 3 (13.0)
H-MRD (n = 14) 11 (78.6)
Del(17p) and/or TP53 mutated .01
At least one present (n = 43) 10 (23.3)
Neither present (n = 78) 5 (6.4)
Del(11q) .03
Present (n = 38) 1 (2.6)
Absent (n = 80) 13 (16.3)
Del(11q) without del(17)p§ .25
Present (n = 32) 1 (3.1)
Absent (n = 58) 7 (12.1)
IGVH status .14
Mutated (n = 38) 2 (5.3)
Unmutated (n = 84) 13 (15.5)
No. of previous therapies .79
1 (n = 78) 9 (11.5)
$ 2 (n = 52) 7 (13.5)
Bulky disease (largest lymph node diameter), cm 1.0
, 5 (n = 67) 9 (13.4)
$ 5 (n = 53) 7 (13.2)
Residual disease at EOCT .08
Low nodal burden (, 1.5 cm;
n = 64)
5 (7.8)
Intermediate nodal burden
($ 1.5 to , 2 cm; n = 23)
2 (8.7)
High nodal burden
($ 2 cm; n = 39)
9 (23.1)
Abbreviations: EOCT, end of combination therapy; EOT, end of therapy; (H-),
high level; IGVH, immunoglobulin variable region heavy chain; (L-), low level;
(u)MRD, (undetectable) measurable residual disease; PB, peripheral blood; PD,
disease progression.
*Categories do not sum to 130 as data elements are missing for some patients.
†P value is based on Fisher’s exact test.
‡MRD status was not available for 10 patients at EOT.
§In Do¨hner hierarchical model.
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MRD at EOT, PD occurred in three (13%) of 23 and 11
(79%) of 14 patients with L-MRD and H-MRD, re-
spectively (Fig 4). Details of the two patients in the uMRD
group with PD can be found in the Data Supplement.
Univariate analysis of 130 patients who completed
treatment demonstrated a strong association betweenMRD
level and progression, with uMRD being associated with
better outcomes (Table 1). More patients without del(17p)
and/or mutated TP53 had uMRD at EOT and remained PD
free compared with those with del(17p) and/or mutated
TP53 (Appendix Fig A5B, online only). The presence of
minor residual adenopathy on CT scan at the EOCT visit
was not predictive of achieving uMRD at EOT, nor of
subsequent relapse (Table 1 and Appendix Fig A5C,
online only).
Of patients with uMRD at EOT, most sustained uMRD (58
[70%] of 83 patients; Appendix Fig A5D, online only),
whereas 25 (30%) of 83 patients developed detectable
MRD. With current follow-up, this was typically L-MRD
(21 [25%] of 83 patients), all of whom remained PFS
event free. Four patients who had uMRD at EOT de-
veloped H-MRD (four [5%] of 83 patients) within a range
of 6.0 to 13.4 months, one of whom subsequently de-
veloped PD, per International Workshop on CLL (iwCLL)
criteria. Median time off venetoclax to the last MRD test
in these 25 patients was 11.1 months (range, 5.3 to
19.3 months). Residual adenopathy on CT scan at the
EOCT visit was not predictive of conversion from uMRD
after drug cessation (Appendix Fig A5C). Of 25 patients
who were uMRD at EOT and converted to detectable
TABLE 2. MRD Status in All Patients and By Baseline Clinical and Cytogenetic Factors at EOCT
Factor
Venetoclax-Rituximab Bendamustine-Rituximab
No. uMRD (%) L-MRD (%) H-MRD (%) No. uMRD (%) L-MRD (%) H-MRD (%) P*
All patients† 194 62.4 19.1 4.6 195 13.3 23.1 29.2 , .001
Age group, years
, 65 97 61.9 15.5 6.2 89 12.4 15.7 31.5 , .001
$ 65 97 62.9 22.7 3.1 106 14.2 29.2 27.4 , .001
Sex
Male 136 61.0 20.6 3.7 151 10.6 23.8 31.8 , .001
Female 58 65.5 15.5 6.9 44 22.7 20.5 20.5 .001
No. of prior regimens
1 111 64.0 21.6 4.5 117 12.0 26.5 31.6 , .001
. 1 83 60.2 15.7 4.8 78 15.4 17.9 25.6 , .001
Bulky disease (largest lymph node diameter), cm
, 10 161 61.5 19.9 5.6 158 11.4 24.7 29.7 , .001
$ 10 23 65.2 8.7 0 27 14.8 11.1 29.6 .0003
b2-microglobulin, mg/L
# 3.5 64 64.1 18.8 3.1 59 10.2 22.0 30.5 , .001
. 3.5 125 62.4 17.6 5.6 127 15.7 24.4 29.1 , .001
IGVH
Unmutated 123 61.0 18.7 6.5 123 14.6 21.1 31.7 , .001
Mutated 53 64.2 22.6 1.9 51 15.7 27.5 21.6 , .001
11q
Deleted 61 65.6 11.5 4.9 64 10.9 26.6 29.7 , .001
Not deleted 112 62.5 24.1 5.4 105 16.2 21.0 28.6 , .001
Del(17p) and/or TP53 mutated
Yes 72 56.9 19.4 2.8 75 5.3 18.7 34.7 , .001
No 106 66.0 18.9 6.6 95 20.0 26.3 25.3 , .001
Abbreviations: EOCT, end of combination therapy; (H-), high level; IGVH, immunoglobulin variable region heavy chain; (L-), low level; (u)MRD,
(undetectable) measurable residual disease; PD, progressive disease.
*P value is based on Fisher’s exact test.
†Data from 43 patients were missing: 14 in the venetoclax-rituximab arm and 29 in the bendamustine-rituximab arm. There were 13 PD/death/withdrawals
in the venetoclax-rituximab arm and 38 PD/death/withdrawals in the bendamustine-rituximab arm before the EOCT visit.
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FIG 3. (A) Measurable residual disease (MRD) response over time with venetoclax-rituximab versus bendamustine-rituximab. (B) Landmark progression-free
survival (PFS) analysis according to peripheral blood (PB)MRD status at end of combined therapy (EOCT) response visit (intent-to-treat [ITT] population). The
analysis subset includes patients who have not experienced progression, died, or withdrawn from study before EOCT response (continued on following page)
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MRD, 10 had residual disease at the EOCT visit with at
least one lymph node having a longest perpendicular
diameter of 2 cm or greater, three had residual disease
with at least one lymph node 1.5 cm or greater to less
than 2 cm at EOCT, 11 had no residual disease at EOCT,
and one patient had no CT scan.
Safety
An overview of safety data for the MURANO trial during the
combination and single-agent periods is provided in the
Data Supplement (Appendix Table A2).
Data Access
Qualiﬁed researchers may request access to individual
patient-level data through the clinical study data request
platform (www.clinicalstudydatarequest.com). Additional
details on Roche’s criteria for eligible studies are available
here: https://clinicalstudydatarequest.com/Study-Sponsors/
Study-Sponsors-Roche.aspx. For additional details on
Roche’s Global Policy on the Sharing of Clinical Informa-
tion and how to request access to related clinical study
documents, see the following: https://www.roche.com/
research_and_development/who_we_are_how_we_work/
clinical_trials/our_commitment_to_data_sharing.htm.
DISCUSSION
Analysis of the phase III global randomized MURANO
study, after a median follow-up of 3 years, demonstrates
substantial clinical beneﬁt with a ﬁxed-duration venetoclax-
rituximab treatment regimen. With all patients having
completed planned treatments, and with a median follow-
up of 9.9 months off therapy, PFS with venetoclax-rituximab
was superior to bendamustine-rituximab; improvements
were consistent across all subgroups. These results sub-
stantiate the previously reported ﬁndings from the MUR-
ANO trial.20 Incidence of PD after the completion of
venetoclax was modest at 12%. Improved OS with
venetoclax-rituximab was observed, despite a high rate of
use of novel targeted agents in patients with PD in the
bendamustine-rituximab arm. With longer follow-up, no
new safety signals were identiﬁed, single-agent venetoclax
after combination was tolerable, and themajority of patients
completed planned treatment.
Higher rates of uMRD with venetoclax-rituximab were
achieved at the EOCT response visit and as best MRD
response compared with bendamustine-rituximab ther-
apy.20 The high uMRD response rate was found in all
molecular and clinical subsets, including patients with
high-risk features, such as del(17p) and/or TP53mutation.
Residual H-MRD was less frequent in the venetoclax-
rituximab arm than in the bendamustine-rituximab arm.
Patients in each treatment arm with uMRD in PB at the
EOCT response visit demonstrated prolonged PFS relative
to patients who had detectable MRD. Prolonged PFS was
also observed within the group with persistent MRD for
those with L-MRD versus those with H-MRD.
Similar to observations with CIT in the ﬁrst-line setting,
eradication of detectable MRD at EOCT using venetoclax-
rituximab was predictive of favorable outcome, including in
patients with CR and PR/nodular PR.13-18 Longer follow-up
is needed to determine the impact of PB MRD status
among patients achieving CR or CR with incomplete he-
matologic recovery who were treated with venetoclax-
rituximab. These data highlight that uMRD is an impor-
tant goal of therapy irrespective of treatment approach.
These ﬁndings also conﬁrm attainment of PB uMRD as
a surrogate for PFS among patients who are treated with
venetoclax-rituximab. In the venetoclax-rituximab study
arm, we observed that high rates of uMRD were sustained
over time and also seen at EOT among patients who
completed 2 years of venetoclax treatment (64%). Of
10
14
23
83
Missing
High-MRD
Low-MRD
uMRD
At EOT (n = 130)
1 pt with PD
With 9.9 months
median follow-up
off venetoclax
14
2 pts
with PD
58 
1 pt with PD
21
4
3 pts without PFS
event
11 pts with PD
1 pt
with PD
9
14
All without
PFS event
FIG 4. Measurable residual disease (MRD) changes in venetoclax-
rituximab arm patients who were without a progression-free survival
(PFS) event at end of treatment (EOT; n = 130). (u)MRD, (un-
detectable) measurable residual disease; pt, disease progression; pt,
patient.
(Continued). visit. MRD PB status derived from combining allele-speciﬁc oligonucleotide–polymerase chain reaction (ASO–PCR) and ﬂow cytometry results.
(C) Landmark PFS analysis in the venetoclax-rituximab arm according to PBMRD status and clinical response status at EOCT response visit (ITT population).
The analysis subset includes patients who have not progressed, died, or withdrawn from study and have a complete response (CR), CR with incomplete
hematologic recovery (CRi), nodular partial response (PR), or PR per investigator assessment at EOCT response visit. MRD PB status derived from combining
ASO–PCR and ﬂow cytometry results. BR, bendamustine-rituximab; C, cycle; CR, complete response; D, day; EOT, end of treatment; H-MRD, high-level MRD
($ 1022); HR, hazard ratio; L-MRD, low-level MRD (1024 to, 1022); (u)MRD, (undetectable) measurable residual disease; PD, progressive disease; (n)PR,
(nodular) partial response; VenR, venetoclax-rituximab.
Journal of Clinical Oncology 7
Fixed-Duration Venetoclax-Rituximab Improves Outcomes in R/R CLL
Downloaded from ascopubs.org by University of Leeds - Periodicals Department on January 8, 2019 from 129.011.022.236
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
patients in the venetoclax-rituximab arm who developed
detectable MRD after EOT, most became L-MRD and
remained progression free. CLL progression was only ob-
served in two patients with conﬁrmed uMRD status at EOT.
Overall, with a median follow-up after drug cessation of
approximately 10 months, the majority of patients who
were treated with venetoclax-rituximab remained free of
PD by conventional iwCLL criteria—87% at 12 months.
This favorable overall outcome afﬁrms the feasibility of
ﬁxed-duration therapy with venetoclax-rituximab in pa-
tients with R/R CLL, particularly given that either rein-
troduction of venetoclax or Bruton’s tyrosine kinase
inhibitor therapy can lead to resumed disease response
in patients with progression.19,23 To evaluate a larger
number of cases with venetoclax reintroduction and the
likelihood of the resumption of durable disease control,
as has been shown in the context of chronic mye-
loid leukemia after attempted TKI withdrawal,24 the
MURANO protocol has been amended to prospectively
collect such data. In a univariate analysis, conventional
adverse pretreatment risk factors of IGVH mutational
status, number of prior therapies, and disease bulk were
not predictive of disease progression post–drug cessa-
tion. Presence of del(17p) and/or TP53 mutation was
associated with an increased risk of clinical PD post–
treatment cessation (P = .01), but this was confounded
by MRD status. At this follow-up and with just 16 PD
events to date, MRD status at EOT is emerging as a strong
indicator of the risk of disease recurrence and might
imply that patients with H-MRD are better managed by
continuing venetoclax. Residual minor adenopathy on
CT assessment—here on the basis of EOCT visit, as not
all patients had repeat imaging at EOT—was not asso-
ciated with an increased risk of disease recurrence,
which suggests that these persisting imaging ﬁndings
may not represent a reservoir of viable disease. As
previously reported after front-line treatment,17 serial
MRD assessment may identify those patients with rising
disease burden many months before clinical disease
recurrence, and our data suggest that patients frequently
transition through intermediate MRD levels, which does
not uniformly predict imminent relapse by iwCLL criteria.
Longer observation of this cohort will be needed to deﬁne
the spectrum of CLL doubling times and potentially
predict the timing of clinical recurrence, which will allow
for therapy reintroduction before patients reach high
tumor burden status. Even if a proportion of patients are
ultimately destined to develop PD by iwCLL criteria and
require such retreatment as venetoclax reintroduction,
a number of years off drug would have quality-of-life,
toxicity, and societal economic beneﬁt. This would also
minimize clonal selection pressure, relevant with other
targeted therapies.5-7
This longer follow-up conﬁrms that ﬁxed-duration
venetoclax-rituximab therapy delivers durable clinical
response and a survival advantage over bendamustine-
rituximab therapy. Higher rates of PB uMRD at the EOCT
response visit predicted prolonged beneﬁt independent
of clinical response, and patients with L-MRD also
achieved better outcomes than did those with H-MRD. In
the venetoclax-rituximab arm, high rates of uMRD were
also sustained over time, and most of these patients
remained PD free after drug cessation. These data
support the feasibility of a ﬁxed duration of venetoclax-
rituximab in R/R CLL. Furthermore, levels of MRD are
highly predictive of duration of remission during and after
venetoclax cessation.
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APPENDIX
Excluded
Met exclusion criteria/did not
   meet inclusion criteria
Withdrew consent
Other reason
Did not receive rituximab                    (n = 7)
Discontinued venetoclax                 (n = 6)
   during ramp-up period             
Tested positive for HBsAg during  (n = 1)
   venetoclax ramp-up period and
   did not start rituximab 
Did not receive either bendamustine or 
rituximab                                             (n = 7)
Withdrew consent                         (n = 6)
Withdrawn by physician               (n = 1)
Received at least one dose of
either venetoclax or rituximab 
(n = 194; received 
venetoclax-rituximab [n = 187])
Received at least one dose of 
either bendamustine or rituximab 
(n = 188)
Discontinued bendamustine plus
rituximab                                          (n = 27)
Died (n = 3)
Experienced disease progression (n = 6)
Had adverse events                         (n = 11)
Discontinued for other reason          (n = 7)
Discontinued venetoclax during     (n = 49)
   monotherapy                                    
Experienced disease progression   (n = 21)
Had adverse events                          (n = 20)
Discontinued for other reason          (n = 8)
Completed 2 years of 
venetoclax without progression 
(n = 130)
Randomly assigned
(n = 389)
Patients screened
(N = 489)
Completed venetoclax-rituximab 
(n = 174)
Completed bendamustine-rituximab
(n = 154)
Assigned to venetoclax-rituximab
(n = 194)
Assigned to bendamustine-rituximab
(n = 195)
Discontinued venetoclax during
combination therapy (includes ramp-up 
period; n = 15)
Died  (n = 2)
Experienced disease progression (n = 1)
Had adverse events (n = 9)
Discontinued for other reason   (n = 3)
(n = 13)
Had adverse events (n = 10)
Discontinued for other reason   (n = 3)
(n = 100)
(n = 78)
(n = 5)
(n = 17)
Discontinued rituximab
FIG A1. Patient disposition. HBsAG, hepatitis B surface antigen
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VenR
(n = 194)
BR
(n = 195)
Characteristic/Biomarker
Total
No. No.
Median†
(months) No.
Median
(months)
Hazard
Ratio
95% Wald
CI
VenR
Better
BR
Better
All patients
Age group, years
< 65
 65
Risk status* 
Low
High
Geographic region
United States/Canada
Australia/New Zealand
Western Europe
Central and Eastern 
Europe
Asia
No. of prior regimens
1
2
 3
Refractory v relapse to most recent prior therapy‡
Refractory
Relapse
Chromosome 17p deletion (central)
No
Yes
TP53 mutated (central)
No
Yes
IGVH
Mutated
Unmutated
389 194 NE 195 17.0 0.19 (0.14 to 0.27)
186 97 NE 89 15.4 0.17 (0.11 to 0.27)
203 97 NE 106 22.3 0.21 (0.14 to 0.33)
211 104 NE 107 15.4 0.21 (0.14 to 0.31)
178 90 44.3 88 23.3 0.17 (0.10 to 0.28)
34 16 44.3 18 15.8 0.18 (0.06 to 0.52)
86 44 NE 42 24.5 0.26 (0.13 to 0.52)
130 64 NE 66 15.5 0.17 (0.09 to 0.30)
228 111 44.3 117 16.6 0.16 (0.10 to 0.25)
330 164 NE 166 18.6 0.16 (0.11 to 0.23)
250 127 NE 123 21.4 0.19 (0.13 to 0.29)
276 144 NE 132 21.2 0.16 (0.10 to 0.24)
246 123 44.3 123 15.7 0.16 (0.11 to 0.24)
92 46 NE 46 15.4 0.21 (0.11 to 0.39)
99 48 36.0 51 12.9 0.25 (0.15 to 0.43)
104 53 NE 51 24.2 0.16 (0.07 to 0.33)
101 58 NE 43 21.2 0.24 (0.13 to 0.43)
53 30 31.9 29 13.6 0.40 (0.20 to 0.79)
8 4 NE 4 13.6 0.46 (0.07 to 2.86)
131 66 NE 65 17.3 0.16 (0.09 to 0.29)
60 25 NE 35 12.9 0.26 (0.12 to 0.55)
1/100 1 100
FIG A2. Prespeciﬁed subgroup analysis of investigator-assessed progression-free survival (PFS). (*) Low risk: deﬁned as relapse more than 12 months after
chemotherapy or 24 months after chemoimmunotherapy. High risk: deﬁned as harboring 17p deletion or no response to front-line chemotherapy-containing
regimen or relapsed within 12months after chemotherapy or within 24months after chemoimmunotherapy. (†) Medians in the VenR arm could not be reliably
estimated due to too few patients at risk. (‡) Deﬁned as per iwCLL guidelines. Relapsed disease: a patient who previously achieved a complete or partial
response, but after a period of 6 months or more demonstrates evidence of progression. Refractory disease: treatment failure or disease progression within
6 months of the last anti-leukemia. BR, bendamustine-rituximab; IGVH, immunoglobulin variable region heavy chain; iwCLL, International Workshop on CLL;
NE, not estimable; VenR, venetoclax-rituximab
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No. (%)
ASO-PCR r (P)
 10–4 < 10–4
CD22/CD81 CLL 0.92 (< .001)
Bendamustine-rituximab (n = 697) MRD flow 10–4
MRD flow 10–4
MRD flow 10–4
MRD flow 10–4
570 (81.8) 20 (2.9) 0.94
33 (4.7) 74 (10.6)
Venetoclax-rituximab (n = 1,026) 301 (29.3) 51 (5.0) 0.9
116 (11.3) 558 (54.4)
MRD flow 10–4
MRD flow 10–4
MRD flow 10–4
MRD flow 10–4
CD20/CD38 CLL 0.92 (< .001)
Bendamustine-rituximab (n = 697) 566 (81.2) 22 (3.2) 0.94
37 (5.3) 72 (10.3)
Venetoclax-rituximab (n = 1,026) 299 (29.1) 55 (5.4) 0.86
118 (11.5) 554 (54.0)
MRD flow 10–4
MRD flow 10–4
MRD flow 10–4
MRD flow 10–4
CD79b/CD43 CLL 0.86 (< .001)
Bendamustine-rituximab (n = 697) 565 (81.1) 20 (2.9) 0.87
38 (5.5) 74 (10.6)
Venetoclax-rituximab (n = 1,026) 298 (29.0) 62 (6.0) 0.85
119 (11.6) 547 (53.3)
-1
-2
-3
-4
-5
-6
-6 -5 -4 -3 -2 -1 0 1
0
1
202
755 49
853
r = 0.89
P < .001
AS
O-
PC
R 
(lo
g1
0)
Flow (log10)
A
B
FIG A3. SO-PCR–ﬂow concordance. (A) MRD concordance between MRD peripheral blood from ﬂow and PCR
(numerical): intent-to-treat population. (B) Correlation of quantitative MRD levels between ASO–PCR and all three
antibody pairs by treatment arm. Based on data as of cut-off May 8, 2018. For MRD values below the limit of
detection (LOD), LODs were represented in the graph. Correlation coefﬁcient r and P value (t-test) are for positive
sample only. ASO-PCR, allele-speciﬁc oligonucleotide–polymerase chain reaction; MRD, measurable residual
disease.
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FIG A5. (A) Sankey plot is a ﬂow diagram showing MRD kinetics in the intent-to-treat population in the venetoclax-rituximab study arm (N = 194) over the
course of the study. The width of links between the categories within the vertical bars at each assessment time point represents the proportion of patients; the
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top of the chart. (B) MRD status at EOT in venetoclax-rituximab arm patients according to baseline del(17p) and/or TP53 status. (C) MRD status at EOT in
venetoclax-rituximab arm patients according to residual disease status at the EOCT visit. (D) Kaplan-Meier plot of conversion to MRD1 in patients who had
uMRD in peripheral blood at EOT (N=83). BM samples were not mandated in the protocol at EOT. EOT, end of treatment; PD, disease progression; (u)MRD,
(undetectable) measurable residual disease; VenR, venetoclax-rituximab.
Journal of Clinical Oncology
Fixed-Duration Venetoclax-Rituximab Improves Outcomes in R/R CLL
Downloaded from ascopubs.org by University of Leeds - Periodicals Department on January 8, 2019 from 129.011.022.236
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
TABLE A1. Hierarchical Algorithm for Combining MRD Results from ASO–PCR and Flow Assays
Step No. Step
1 Detectable MRD positive by either ASO–PCR or ﬂow = detectable MRD
2 If a sample is not detectable MRD with Step 1 and undetectable MRD by ASO–PCR and/or ﬂow = undetectable MRD
3 If MRD undetermined by both ASO–PCR and ﬂow = MRD undetermined*
Abbreviations: ASO–PCR, allele-speciﬁc oligonucleotide–polymerase chain reaction; MRD, measurable residual disease.
*MRD undetermined status and missing are treated as MRD positive in the intent-to-treat analysis.
TABLE A2. Overview of Safety Data for MURANO During Combination and Single-Agent Periods
Variable
Venetoclax-Rituximab
Combination Therapy Period (n = 194)
Venetoclax Single-Agent
Period* (n = 171)
Total No. of patients with $ 1 AE 192 (99.0) 151 (88.3)
AE leading to withdrawal from venetoclax† 15 (7.7) 17 (9.9)
AE leading to dose reduction 24 (12.4) 7 (4.1)
AE leading to dose interruption 125 (64.4) 44 (25.7)
Grade 3-4 AEs 145 (74.7) 59 (34.5)
Fatal AEs 8 (4.1) 7 (4.1)
NOTE. Data are presented as No. (%).
Abbreviation: AE, adverse event.
*For the purposes of the analysis, AEs that occurred with an onset date of more than 90 days after the last rituximab dose in patients who had received at
least one venetoclax dose more than 90 days after the last rituximab dose were considered to have occurred during the venetoclax single-agent treatment
period. AEs that occurred with an onset date before 90 days after the last rituximab dose were considered to have occurred during the venetoclax-rituximab
combination treatment period.
†There was a total of 41 AEs that resulted in withdrawal from venetoclax therapy in 32 patients. AEs leading to withdrawal of venetoclax therapy during the
combination period were neutropenia (n = 4; 2.1%), thrombocytopenia (n = 3; 1.5%), neoplasms (metastasis [unspeciﬁed], colorectal cancer [n = 2; 1.0%]),
febrile neutropenia (n = 1; 0.5%), anemia (n = 1; 0.5%), autoimmune hemolytic anemia (n = 1; 0.5%), acute respiratory failure (n = 1; 0.5%), appendicitis
(n = 1; 0.5%), peritoneal tuberculosis (n = 1; 0.5%), pneumonia (n = 1; 0.5%), pyrexia (n = 1; 0.5%), status epilecticus (n = 1; 0.5%), and sudden cardiac
death (n = 1; 0.5%). AEs leading to withdrawal of venetoclax during the single-agent period were neoplasms (colorectal cancer, metastatic malignant melanoma,
pancreatic cancer, lung and peritoneal neoplasms [n = 5; 2.6%]), neutropenia (n = 3; 1.5%), thrombocytopenia (n = 2; 1.0%), ALT increase (n = 1; 0.5%),
ascites (n = 1; 0.5%), asthenia (n = 1; 0.5%), autoimmune hemolytic anemia (n = 1; 0.5%), Crohn’s disease (n = 1; 0.5%), diarrhea (n = 1; 0.5%), immune
thrombocytopenia purpura (n= 1; 0.5%), hydrothorax (n =1; 0.5%), lung infection/pneumonia (n =2; 1.0%), suddendeath (n= 1; 0.5%), and vertigo (n =1; 0.5%).
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TABLE A3. Characteristics of Patients (n = 25) Who Experienced Progression
Before End of Therapy
Characteristic Value
No. of prior lines of therapy
1 14 (56)
2 8 (32)
3 3 (12)
Del17p
Deleted 6 (24)
Normal 16 (64)
Unknown 3 (12)
P53 mutation
Mutated 12 (48)
Not mutated 12 (48)
Unknown 1(4)
P53 mutation and/or del17p
No 9 (36)
Yes 13 (52)
Unknown 3 (12)
Median age, years (mean; range) 63 (59.7; 28-81)
NOTE. Data are presented as No. (%), unless otherwise noted.
TABLE A4. Study Treatment Exposure in Safety-Evaluable Patients
Variable
Venetoclax-Rituximab
(n = 194)
Venetoclax-Rituximab
Combination Period
(n = 194)
Venetoclax-Rituximab Monotherapy
Period* (n = 187)
Bendamustine-
Rituximab
(n = 188)
Venetoclax treatment duration
(months)
No. 194 194 173 NA
Mean (SD) 21.0 (7.2) 6.7 (2.1)† 16.0 (4.2) NA
Median 24.4 6.7† 17.7 NA
Min-max 0.1-27.9 0.1-24.9† 0.5-21.9 NA
Dose intensity (%)
No. 189 189 172 188
Mean (SD) 89.6 (17.1) 91.6 (14.5) 90.2 (18.3) 96.7 (8.2)
Median 97.4 97.2 99.3 100
Min-max 26-100 36-100 23-100 50-100
Abbreviations: NA, not applicable; SD, standard deviation.
*From day 29 after the last dose of rituximab.
†One patient was not exposed to rituximab. In this patient, the duration of venetoclax exposure was treated as being in the combination period.
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TABLE A5. Response to Subsequent Therapy After PD in the Venetoclax-Rituximab and Bendamustine-Rituximab Arms
Patients Receiving Subsequent Therapy
Treatment Arm Total CR PR* SD PD NE/NA
Venetoclax-rituximab arm
Ibrutinib monotherapy/combination 8 0 2 0 0 6
Venetoclax monotherapy 3 0 1 1 0 1
Idelalisib monotherapy/combination 1 0 0 1 0 0
Chemotherapy and/or immunotherapy 14 1 2 2 3 6
Investigational product (other) 1 0 0 0 1 0
Bendamustine-rituximab arm
Ibrutinib monotherapy/combination 46 5 22 4 1 14
Venetoclax monotherapy 7 0 2 0 0 5
Idelalisib monotherapy/combination 7 1 4 0 1 1
Chemotherapy and/or immunotherapy 20 5 5 3 2 5
Investigational product
BTKi† 7 0 4 2 1 0
Non-BTKi 3 0 2 0 1 0
Other 1 0 1 0 0 0
NOTE. Data are given as No.
Abbreviations: BTKi, Bruton’s tyrosine kinase inhibitor; CR, complete response; NA, not assessed; NE, not evaluable; PD, disease progression; PR, partial
response; SD, stable disease.
*Includes one patient who achieved a nodular partial response.
†Excludes ibrutinib.
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